Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An epilepsy syndrome that occurs between 28 days to one year of life.
No HPO annotations are available for this condition.
Since the original description of SYNGAP1-related intellectual disability (SYNGAP1-ID) in three individuals , more than 50 affected individuals with detailed clinical information have been reported [, , , , , , , , , , , , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Developmental delay and intellectual disability. The great majority of affected children present with developmental delay or intellectual disability that is typically moderate to severe but can be mild. Early motor development is characterized by hypotonia. The average age at walking was 26 months (range: 10.5 months to 5 years). A subset of these children had an ataxic gait that remained stable or improved over time.
No formal diagnostic criteria have been published for SYNGAP1-related intellectual disability.
SYNGAP1-related intellectual disability (SYNGAP1-ID) should be considered in individuals with developmental delay or intellectual disability with or without:
Generalized epilepsy;
and/or
No approved treatments are currently available for infantile epilepsy syndrome. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with SYNGAP1-related intellectual disability, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 2. Recommended Evaluations Following Initial Diagnosis in Individuals with SYNGAP1-Related Intellectual Disability
Monitor those with seizures as clinically indicated. Assess as needed for anxiety, attention, and aggressive or self-injurious behavior. Monitor developmental progress and educational needs.
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
No clinical trials have been registered for infantile epilepsy syndrome.
105 publications have been identified in PubMed for infantile epilepsy syndrome. Research spans Case Report / Case Series (33%), Epidemiology / Natural History (24%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 33 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:07 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
Autism spectrum disorder (ASD).
The diagnosis of SYNGAP1-ID is established in a proband with developmental delay (DD) or intellectual disability (ID) in whom molecular genetic testing identifies either:
A heterozygous pathogenic (or likely pathogenic) variant in SYNGAP1 (~89%);
or
A deletion of 6p21.3 (~11%).
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
The phenotype associated with SYNGAP1-related intellectual disability (ID) overlaps with that of other disorders of ID and epileptic encephalopathy. Most genes known to be associated with ID (see OMIM Autosomal Dominant Intellectual Developmental Disorder Phenotypic Series) and epileptic encephalopathy (see OMIM Epileptic Encephalopathy, Early Infantile Phenotypic Series) if compatible with walking should be included in the differential diagnosis.
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
Biomarker and diagnostic research for infantile epilepsy syndrome has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Eyes | Ophthalmologic eval | Evidence of strabismus Gastrointestinal/ |
Feeding | Baseline eval for reflux /or constipation; assessment for feeding problems | Refer to gastroenterologist /or feeding therapist for treatment if indicated. |
Musculoskeletal | Assessment for hip rotation/dysplasia, kyphoscoliosis, pes planus | — |
Neurologic | Neurologic eval | Incl EEG brain MRI if seizures are suspected Psychiatric/ |
Behavioral | Neuropsychiatric eval | Screen persons age 12 mos for behavior concerns incl sleep disturbances, ADHD, anxiety, /or traits suggestive of ASD. Miscellaneous/ |
Other | Developmental assessment | Incl motor, speech-language eval, general cognitive, vocational skills. Consultation w/clinical geneticist /or genetic counselor |
Treatment of Manifestations in Individuals with SYNGAP1-Related Intellectual Disability Manifestation/Concern | Treatment | Considerations/Other |
Strabismus | Standard treatment(s) as recommended by ophthalmologist | — |
Swallowing dysfunction | Nasogastric/gastrostomy feeding may be required for persistent feeding issues. | — |
Constipation | Standard treatment as recommended by gastroenterologist | Gastroenterology consultation, if severe |
Hip rotation/dysplasia, kyphoscoliosis, pes planus | Standard treatment as recommended by orthopedist | Orthopedic consultation may be considered. |
Epilepsy | Standardized treatment w/ASMs by experienced neurologist | To date, no guidelines on choice of specific ASMs; Anecdotal reports of improved seizure control w/ketogenic diet in some persons Education of parents regarding common seizure presentations is appropriate. |
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder. Search CURE ID (an FDA website) for information on novel uses of existing drugs for this condition (SYNGAP1 Overview). Note: Any off-label use of drugs should be done at the discretion of the treating physician in conjunction with the affected individual and/or their caregiver and is not endorsed by GeneReviews or the authors of this chapter.
Source: GeneReviews — "SYNGAP1-Related Intellectual Disability"
View trials for infantile epilepsy syndrome
24 |
24% |
Research summaries | 19 | 19% |
Laboratory research | 10 | 10% |
Testing and diagnosis research | 7 | 7% |
Clinical study results | 4 | 4% |
New treatment approaches | 2 | 2% |
Zhang ZB (2026). [PMID: 42013796](https://pubmed.ncbi.nlm.nih.gov/42013796/). *Sleep Med Rev*. [Review / Meta-Analysis]
Gokalp S (2026). [PMID: 42037155](https://pubmed.ncbi.nlm.nih.gov/42037155/). *Am J Med Genet A*. [Case Report / Case Series]
Chachua T (2026). [PMID: 41597133](https://pubmed.ncbi.nlm.nih.gov/41597133/). *Children (Basel)*. [Basic Science / Preclinical]
Möhrle D (2026). [PMID: 41399120](https://pubmed.ncbi.nlm.nih.gov/41399120/). *Autism Res*. [Basic Science / Preclinical]
Berns M (2026). [PMID: 41843312](https://pubmed.ncbi.nlm.nih.gov/41843312/). *Cerebellum*. [Case Report / Case Series]
Sun Y (2026). [PMID: 41416966](https://pubmed.ncbi.nlm.nih.gov/41416966/). *Epilepsia Open*. [Epidemiology / Natural History]
He X (2026). [PMID: 42179731](https://pubmed.ncbi.nlm.nih.gov/42179731/). *Front Hum Neurosci*. [Case Report / Case Series]
Stelling MP (2026). [PMID: 41445022](https://pubmed.ncbi.nlm.nih.gov/41445022/). *ACS Chem Neurosci*. [Basic Science / Preclinical]
Kim DG (2026). [PMID: 41574838](https://pubmed.ncbi.nlm.nih.gov/41574838/). *J Med Chem*. [Gene Therapy / Novel Therapeutics]
Cipri S (2026). [PMID: 41700448](https://pubmed.ncbi.nlm.nih.gov/41700448/). *Am J Med Genet A*. [Case Report / Case Series]